Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Background: Ovarian cancer is the most lethal female genital malignancy. Although cisplatin is the first-line chemotherapy to treat ovarian cancer patients along with debulking surgeries, its efficacy is limited due to the high incidence of cisplatin resistance. ATP citrate lyase (ACLY) has been sho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Wei, Xuan, Shi, Juanjuan, Lin, Qianhan, Ma, Xiaoxue, Pang, Yingxin, Mao, Hongluan, Li, Rui, Lu, Wei, Wang, Yu, Liu, Peishu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8011496/
https://ncbi.nlm.nih.gov/pubmed/33816292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.642229
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller